AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsule.
Selumetinib can also cause cardiomyopathy, ocular toxicity including retinal vein occlusion, retinal pigment epithelial detachment and impaired vision, and increased creatinine phosphokinase. Selumetinib should be withheld, dosage reduced, or permanently discontinued based on the severity of adverse reactions.
- Read more about AstraZeneca Pharma India Limited receives Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg Capsule
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/astrazeneca-pharma-india-limited-receives-import-and-market-permission-in-form-ct-20-from-the-drugs-controller-general-of-india-for-selumetinib-10-mg-and-25-mg-capsule
No comments:
Post a Comment